期刊
GASTROENTEROLOGY CLINICS OF NORTH AMERICA
卷 38, 期 4, 页码 691-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.gtc.2009.07.005
关键词
Inflammatory bowel disease; Infection; Corticosteroids; Immunomodulator; Anti-tumor necrosis factor
资金
- Abbott Laboratories
- Schering-Plough
- UCB
Over the last decade, the medical treatment of inflammatory bowel disease (IBD) has been revolutionized, with increasing use of both immunomodulatory and biologic medications. Corticosteroids have increasingly been associated with an elevated risk of serious and opportunistic infections, both independently and in combination with immunomodulator and biologic agents. There are limited data on the infectious risk of immunomodulators. It is unclear if anti-tumor necrosis factor agents increase overall infectious risk in patients with IBD, but the available literature has demonstrated an increased risk of opportunistic infections, particularly in terms of tuberculosis and histoplasmosis. Combination therapy likely increases the risk of opportunistic infections in patients with IBD but this has not yet been conclusively proved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据